Review: The biological basis of antipsychotic response in schizophrenia (Q37638930)

21 August 2017

1 reference

title

Review: The biological basis of antipsychotic response in schizophrenia (English)

1 reference

21 August 2017

0 references

James M Stone

1

0 references

Philip McGuire

object named as

Philip K McGuire

series ordinal

4

0 references

author name string

Marie Raffin

series ordinal

2

1 reference

PubMed ID

19939865

21 August 2017

Paul Morrison

series ordinal

3

1 reference

PubMed ID

19939865

21 August 2017

language of work or name

English

0 references

publication date

25 November 2009

1 reference

Journal of Psychopharmacology

21 August 2017

1 reference

21 August 2017

24

1 reference

21 August 2017

953-964

1 reference

21 August 2017

7

1 reference

Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia

21 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Schizophrenia: from genes to phenes to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Assessment of the Central Dopaminergic Index of Plasma HVA in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Structural evaluation of the prefrontal cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Striatal metabolic rate and clinical response to neuroleptics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

The changes of biological markers and treatment efficacy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Biological markers and possibilities for predicting therapeutic results in schizophrenia: a methodological contribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Association analysis of the genetic variants of the N-methyl D-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dexamethasone suppression test in depression and other psychiatric illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Molecular pathology of schizophrenia: more than one disease process?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Plasma homovanillic acid as a predictor of response to neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

A revised excitotoxic hypothesis of schizophrenia: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

No association between the DRD3 Ser9Gly polymorphism and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Clozapine response and plasma catecholamines and their metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Management of negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Influence of dopamine agonists on plasma and brain levels of homovanillic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

CATIE and CUtLASS: can we handle the truth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Catechol-O-methyltransferase and Monoamine Oxidase-A Polymorphisms and Treatment Response to Typical and Atypical Neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Drug strategies and treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Brain receptors for antipsychotic drugs and dopamine: direct binding assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Atypical antipsychotics and the relevance of glutamate and serotonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

MRI correlates of treatment response in first episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Genetic variation of 5-HT2A receptor and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Genetic variation of the 5-HT2A receptor and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Pharmacogenetics of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109106959

21 January 2018

Identifiers

DOI

10.1177/0269881109106959

1 reference

21 August 2017

1 reference

PubMed ID

19939865